IP Library › Granted Patent US 9,089,575
Granted Patent B2
US 9,089,575 · App. 14/639,878 · Granted Jul 28, 2015

Substituted benzene compounds

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,089,575
App. No.
14/639,878
Granted
Jul 28, 2015
Kind
B2
Abstract

The present invention relates to substituted benzene compounds. The present invention also relates to pharmaceutical compositions containing these compounds and methods of treating cancer by administering these compounds and pharmaceutical compositions to subjects in need thereof. The present invention also relates to the use of such compounds for research or other non-therapeutic purposes.

Claims (20)

1. A method of treating cancer comprising administering to a human subject in need thereof a therapeutically effective amount of

a pharmaceutically acceptable salt thereof.

2. The method of claim 1 , wherein the cancer is lymphoma or malignant rhabdoid tumor.

3. The method of claim 2 , wherein the cancer is lymphoma.

4. The method of claim 3 , wherein the lymphoma is selected from diffuse large B-cell lymphoma (DLBCL), non-Hodgkin's lymphoma (NHL), and follicular lymphoma.

5. The method of claim 2 , wherein the cancer is malignant rhabdoid tumor.

6. The method of claim 1 , wherein the compound is

or a pharmaceutically acceptable salt thereof.

7. A method of treating cancer comprising administering to a human subject in need thereof a therapeutically effective amount of

a pharmaceutically acceptable salt thereof.

8. The method of claim 7 , wherein the cancer is lymphoma or malignant rhabdoid tumor.

9. The method of claim 8 , wherein the cancer is lymphoma.

10. The method of claim 9 , wherein the lymphoma is selected from diffuse large B-cell lymphoma (DLBCL), non-Hodgkin's lymphoma (NHL), and follicular lymphoma.

11. The method of claim 8 , wherein the cancer is malignant rhabdoid tumor.

12. A method of treating cancer comprising administering to a human subject in need thereof a therapeutically effective amount of

a pharmaceutically acceptable salt thereof.

13. The method of claim 12 , wherein the cancer is lymphoma or malignant rhabdoid tumor.

14. The method of claim 13 , wherein the cancer is lymphoma.

15. The method of claim 14 , wherein the lymphoma is selected from diffuse large B-cell lymphoma (DLBCL), non-Hodgkin's lymphoma (NHL), and follicular lymphoma.

16. The method of claim 12 , wherein the cancer is malignant rhabdoid tumor.

Assignments (6)
TERMINATION AND RELEASE OF SECURITY INTEREST IN PATENTS AT REEL/FRAME: 051057/0848 Recorded Aug 13, 2022
From: BIOPHARMA CREDIT PLC
To: EPIZYME, INC.
Reel/Frame 061165/0501 →
SECURITY INTEREST Recorded Nov 19, 2019
From: EPIZYME, INC.
To: BIOPHARMA CREDIT PLC
Reel/Frame 051057/0848 →
CORRECTIVE ASSIGNMENT TO CORRECT THE ASSIGNOR NAME PREVIOUSLY RECORDED AT REEL: 035192 FRAME: 0898. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT. Recorded Mar 19, 2015
From: EISAI R&D MANAGEMENT CO., LTD.
To: EPIZYME, INC.
Reel/Frame 035226/0782 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 18, 2015
From: EISAI R$D MANAGEMENT CO., LTD.
To: EPIZYME, INC.
Reel/Frame 035192/0898 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 16, 2015
From: KUNTZ, KEVIN WAYNE; CAMPBELL, JOHN EMMERSON
To: EPIZYME, INC.
Reel/Frame 035172/0211 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 16, 2015
From: SEKI, MASASHI
To: EISAI R&D MANAGEMENT CO., LTD.
Reel/Frame 035172/0236 →